Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/gCptmx9VTS
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @DavidHongMD: Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @ProfJohnCrown: Stunning data. https://t.co/Ug92LUJafl
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Stunning data. https://t.co/Ug92LUJafl
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
"Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children" https://t.co/SmKoh8pQtP
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
Now that’s an impressive response rate! Good news for patients with TRK fusion cancers https://t.co/sJ9LFHYfFF
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @StJudeResearch: Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #ch…
RT @StJudeResearch: Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #ch…
RT @DrHBurstein: Great story and editorial on TRK targeting @FAndreMD gives superb commentary https://t.co/0ETdcGW8yQ
This is a great example of precision or personalised medicine having profound impact in the clinic. https://t.co/wNfjOX8AJa
RT @StJudeResearch: Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #ch…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @StJudeResearch: Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #ch…
RT @StJudeResearch: Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #ch…
Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #childhoodcancer patients. @NEJM #LOXO https://t.co/wtNyAP81jv
NEJMの最近の論文ですが筆頭著者が米国研修医時代仲良くしていたひとつ下の後輩だった。優秀だとは思っていたが。。。 https://t.co/UUhO1fOs1r
RT @maljurf100: NEJM Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Chi…
RT @DavidHongMD: Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
Link to NEJM article https://t.co/MMevGDWq51
RT @benweinbergmd: On TRacK to true precision oncology: NEJM https://t.co/foSGXOFc0a
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/tbmeEvS5nb
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/EOwlkAR5lA @NEJM #Cancer https://t.co/uqOT2RmMPV
RT @sloan_kettering: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/4n9XdrWZGt
RT @mreyesm: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/lcS7ajZpxv An important pa…
RT @MLadanyi: Thank you @Aiims1742 ! We are fortunate to have helped identify many of the pts for this remarkable trial via pan-cancer #MSK…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. https://t.co/tHNjSKhrJl
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
Larotrectinib antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type ! Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/wDLGDNkHG2
RT @roelverhaak: Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @roelverhaak: Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Drug Dramatically Shrinks All Tumors in All Ages, Multiple Cancers: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/Bm0yhuAgrI
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @BioGraphica1: #scmsm - Larotrectinib in TRK fusion positive cancers including soft-tissue sarcoma https://t.co/qIXdf5Ysnb
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Cáncer con fusión positiva TRK. Larotrectinib presenta una importante y duradera actividad anti tumoral en pacientes con fusión positiva TRK, independientemente de la edad de los pacientes y del tipo de tumor. https://t.co/UIWgwOnekY
El futuro ya está aquí, un gran paso hacia la medicina personalizada. https://t.co/LEV3CDGeSj
RT @DavidHongMD: Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @benweinbergmd: On TRacK to true precision oncology: NEJM https://t.co/foSGXOFc0a
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
Remarkable https://t.co/clXsEydWgl
Congratulations 🎊🍾 @alexdrilon !! https://t.co/XtHaLPgOza
Science Twitter is, in majority, exceedingly illuminating, fun, and helpful. Disappointing when when people use the platform to snarkily drive their agenda. Sarcasm is the easy way out. https://t.co/vaXoZjXT24
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/YuithGm9d8
Wow! Great @NEJM paper showing over 70% response rates and durable responses over 1 year to targeted therapy! #PrecisionMedicine #Cancer https://t.co/wYZPx7zqV5
The success of #Larotrectinib with varying tumor types highlights the importance of our molecular approach to #PrecisionOncology, where the presence of the fusion drives the response. #NTRK fusions are rare - with small targeted gene panels, these would be
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @emiliomonteb: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [NEJM] https://t.co/zmn31lmv14
RT @eyoste: Loxo 101 study has impressive results, including in childhood cancer patients https://t.co/8cksEHI8oY
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al @NEJM https://t.co/5…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.c…
RT @IshwariaMD: Bravo, @DavidHongMD!!👏👏 #Larotrectinib approaches the ideal that we work toward - tumor shrinkage that lasts with minimal s…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Thread. The imprecision of promises. 👇 https://t.co/IC3esMiSza
RT @mreyesm: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/lcS7ajZpxv An important pa…
RT @benweinbergmd: On TRacK to true precision oncology: NEJM https://t.co/foSGXOFc0a